SARS-COV-2 INFECTIONS IN CHILDREN : MOROCCAN COHORT STUDY
- 1. Laboratory of clinical immunology, infection and autoimmunity (LICIA), Faculty of Medicine and Pharmacy, Hassan II University , Casablanca, Morocco
- 2. Department of Clinical Immunology and Infectious Pediatrics, Abderrahim Harouchi Hospital, Ibn Rochd University Hospital Center, Casablanca, Morocco
- 3. Laboratory of clinical immunology, infection and autoimmunity (LICIA), Faculty of Medicine and Pharmacy, Hassan II University , Casablanca, Morocco; Department of Clinical Immunology and Infectious Pediatrics, Abderrahim Harouchi Hospital, Ibn Rochd University Hospital Center, Casablanca, Morocco
- 4. Paediatric intensive care unit, Abderrahim Harouchi Hospital, Ibn Rochd University Hospital, Casablanca, Morocco
- 5. Laboratory of clinical immunology, infection and autoimmunity (LICIA), Faculty of Medicine and Pharmacy, Hassan II University , Casablanca, Morocco; Department of Clinical Immunology and Infectious Pediatrics, Abderrahim Harouchi Hospital, Ibn Rochd University Hospital Center, Casablanca, Morocco; Immunopathology-Immunotherapy-Immunomonitoring Laboratory, Faculty of Medicine, Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco; Immunology Laboratory, Ibn Rochd University Hospital, Casablanca, Morocco
Description
Introduction. Multisystem inflammatory syndrome in children (MIS-C), initially called Pediatric Inflammatory Multisystem Syndrome (PIMS), is a postinfectious disease related to COVID-19 characterized by fever, elevated inflammatory markers, severe systemic inflammation, and shock occurring about 4 to 6 weeks after SARS-CoV-2 infection. The risk factors for MIS-C development and long-term outcomes remain unclear. This study aims to describe the epidemiological, clinical, paraclinical, and evolutionary profile of children with MIS-C during the COVID-19 pandemic in the Pediatrics infectious disease department.
Matériels et méthodes. A prospective study was conducted on pediatric patients diagnosed with MIS-C from March 2020 to March 2023 at the Clinical Immunology and Infectious Pediatrics Department, Abderrahim Harouchi Mothers and Children's Hospital. Patients were investigated for MIS-C using WHO criteria. Data on demographics, clinical, biological, therapeutic, and evolutionary aspects were collected.
Résultats. Among 52 children meeting WHO criteria, the median age was 6 years with a sex ratio of 1.16. SARS-CoV-2 PCR was positive in 19% of patients, serology positive in 80%, anti-SARS-CoV-2 IgM positive in 48%, and IgG positive in 60%. Clinical manifestations included fever in all cases, respiratory and gastrointestinal symptoms in 58% and 44% respectively, shock in 17%, and neurological signs in 8%. Elevated D-dimer levels were noted in 58%. Treatment consisted of intravenous human immunoglobulin combined with methylprednisolone in all patients.
Conclusion. Despite significant morbidity associated with MIS-C, most patients have favorable outcomes. Determining the pathophysiology of MIS-C remains a particular challenge.
Messages clés.
- MIS-C is a severe post-COVID-19 inflammatory syndrome in children occurring weeks after infection.
- Clinical presentation includes fever, respiratory and gastrointestinal symptoms, shock, and neurological signs.
- Treatment with intravenous immunoglobulin and methylprednisolone leads to favorable prognosis in most cases.
Notes
Files
mpjmr-2026-0019.pdf
Additional details
Related works
- Is identical to
- Poster: https://journal.meetingspremium.com/p/2026-0019 (URL)